Dirk Petersen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dirk Petersen has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Dirk Rades
Department of Radiation Oncology, University of Luebeck, 23562 Luebeck, Germany
1 shared publication - Jürgen Dunst
Universitätsklinikum Schleswig-Holstein, Campus Kiel
1 shared publication - Kathrin Dellas
Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
1 shared publication - Kristina Martens
Department of Radiotherapy, University of Luebeck, Ratzeburger Allee 160, Luebeck 23538, Germany
1 shared publication - Matteo Mario Bonsanto
Department of Neurosurgery, University of Luebeck, 23562 Luebeck, Germany
1 shared publication - Thekla Meyners
Department of Radiotherapy, University of Luebeck, Ratzeburger Allee 160, Luebeck 23538, Germany
1 shared publication
Latest Publications
- Open Access
- 3 July 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 162
The prognostic value of tumor necrosis in patients undergoing stereotactic radiosurgery of brain metastases
This retrospective study investigated the outcome of patients with brain metastases after radiosurgery with special emphasis on prognostic impact of visible intratumoral necrosis on survival and local control. From 1998 through 2008, 149 patients with brain metastases from solid tumors were treated with stereotactic radiotherapy at Luebeck University. Median age was 58.4 years with 11%, 78%, 10% in recursive partitioning analysis (RPA) classes I, II, III, respectively. 70% had 1 metastasis, 29% 2-3 metastases, 2 patients more than 3 metastases, 71% active extracranial disease. Median volume of metastatic lesions was 4.7 cm3, median radiosurgery dose 22 Gy (single fraction). 71% of patients received additional whole-brain irradiation (WBI). All patients were analyzed regarding survival, local, distant failure and prognostic factors, side effects and changes in neurologic symptoms after radiotherapy. The type of contrast-enhancement in MR imaging was also analyzed; metastatic lesions were classified as containing necrosis if they appeared as ring-enhancing with central areas of no or minimal contrast enhancement. Median survival was 7.0 months with 1-year and 5-year survival rates of 33% and 0.4%, respectively. Tumor necrosis (ring-enhancement) was visible on pretreatment MRI scans in 56% of all lesions and lesions with necrosis were larger than non-necrotic lesions (6.7 cm3 vs. 3.2 cm3, p = 0.01). Patients with tumor necrosis had a median survival of 5.4 months, patients without tumor necrosis 7.2 months. Local control rate in the irradiated volume was 70%, median survival without local failure 17.8 months. Control in the brain outside the irradiated volume was 60%, median survival without distant failure 14.0 months. Significant prognostic factors for overall survival were KPS (p = 0.001), presence of tumor necrosis on pretreatment MRI (p = 0.001) with RPA-class and WBI reaching marginal significance (each p = 0.05). Prognostic impact of tumor necrosis remained significant if only smaller tumors with a volume below 3.5 cm3 (p = 0.03). Side effects were rare, only one patient suffered from serious acute side effects. Results of this retrospective study support that stereotactic radiotherapy is an effective treatment option for patients with metastatic brain lesions. The prognostic impact of visible tumor necrosis (ring-enhancement) on pretreatment MRI scans should be further investigated.
- 3 July 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 162
Open AccessThe prognostic value of tumor necrosis in patients undergoing stereotactic radiosurgery of brain metastases
This retrospective study investigated the outcome of patients with brain metastases after radiosurgery with special emphasis on prognostic impact of visible intratumoral necrosis on survival and local control. From 1998 through 2008, 149 patients with brain metastases from solid tumors were treated with stereotactic radiotherapy at Luebeck University. Median age was 58.4 years with 11%, 78%, 10% in recursive partitioning analysis (RPA) classes I, II, III, respectively. 70% had 1 metastasis, 29% 2-3 metastases, 2 patients more than 3 metastases, 71% active extracranial disease. Median volume of metastatic lesions was 4.7 cm3, median radiosurgery dose 22 Gy (single fraction). 71% of patients received additional whole-brain irradiation (WBI). All patients were analyzed regarding survival, local, distant failure and prognostic factors, side effects and changes in neurologic symptoms after radiotherapy. The type of contrast-enhancement in MR imaging was also analyzed; metastatic lesions were classified as containing necrosis if they appeared as ring-enhancing with central areas of no or minimal contrast enhancement. Median survival was 7.0 months with 1-year and 5-year survival rates of 33% and 0.4%, respectively. Tumor necrosis (ring-enhancement) was visible on pretreatment MRI scans in 56% of all lesions and lesions with necrosis were larger than non-necrotic lesions (6.7 cm3 vs. 3.2 cm3, p = 0.01). Patients with tumor necrosis had a median survival of 5.4 months, patients without tumor necrosis 7.2 months. Local control rate in the irradiated volume was 70%, median survival without local failure 17.8 months. Control in the brain outside the irradiated volume was 60%, median survival without distant failure 14.0 months. Significant prognostic factors for overall survival were KPS (p = 0.001), presence of tumor necrosis on pretreatment MRI (p = 0.001) with RPA-class and WBI reaching marginal significance (each p = 0.05). Prognostic impact of tumor necrosis remained significant if only smaller tumors with a volume below 3.5 cm3 (p = 0.03). Side effects were rare, only one patient suffered from serious acute side effects. Results of this retrospective study support that stereotactic radiotherapy is an effective treatment option for patients with metastatic brain lesions. The prognostic impact of visible tumor necrosis (ring-enhancement) on pretreatment MRI scans should be further investigated.
- 25 April 2012
- Published by Georg Thieme Verlag KG in RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
- Vol. 184 (S 01) , RK310_2
Häufige Normvarianten - ohne Krankheitswert
Es steht kein Abstracttext zur Verfügung. Korrespondierender Autor: Petersen D Lübeck E-Mail: dirk.petersen@uni-luebeck.de
- 25 April 2012
- Published by Georg Thieme Verlag KG in RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
- Vol. 184 (S 01) , RK310_2
Häufige Normvarianten - ohne Krankheitswert
Es steht kein Abstracttext zur Verfügung. Korrespondierender Autor: Petersen D Lübeck E-Mail: dirk.petersen@uni-luebeck.de
- 1 March 2010
- Published by Georg Thieme Verlag KG in RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
- Vol. 182 (S 01) , WS404_1
Venöse Anomalien in der Schnittbilddiagnostik
Es steht kein Abstracttext zur Verfügung. Korrespondierender Autor: Petersen D Universität zu Lübeck, Institut für Neuroradiologie, Ratzebeurger Allee 160, 23538 Lübeck E-Mail: Dirk.Petersen@uni-luebeck.de
- 1 March 2010
- Published by Georg Thieme Verlag KG in RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
- Vol. 182 (S 01) , WS404_1
Venöse Anomalien in der Schnittbilddiagnostik
Es steht kein Abstracttext zur Verfügung. Korrespondierender Autor: Petersen D Universität zu Lübeck, Institut für Neuroradiologie, Ratzebeurger Allee 160, 23538 Lübeck E-Mail: Dirk.Petersen@uni-luebeck.de